Dr. Jonathan Knowles, Caris Life Sciences Vice Chairman and Chief Scientific Officer, Receives 2010 Scrip Lifetime Achievement A

Dr. Jonathan Knowles, Caris Life Sciences Vice Chairman and Chief Scientific Officer, Receives 2010 Scrip Lifetime Achievement Award  
IRVING, Texas, Nov. 15, 2010 (GLOBE NEWSWIRE) -- Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today congratulates Vice Chairman and Chief Scientific Officer Dr. Jonathan Knowles, recipient of the 2010 Scrip Lifetime Achievement Award. Dr. Knowles accepted the honor during the 6th Annual Scrip Awards ceremony in London on November 4, hosted by Scrip Intelligence.

The internationally-renowned Scrip Awards celebrate outstanding achievements in the pharmaceutical, biotech and allied industries. The esteemed panel of judges acknowledged Dr. Knowles' long academic and commercial career that has been distinguished by his passion for personalized medicine, citing in particular his belief that one of the most important goals in creating new medicines is to understand exactly their effectiveness in treating patients.

"We are honored to have Jonathan as a member of our leadership team and pleased that the Scrip Intelligence organization chose to recognize his numerous achievements to date," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "We look forward to Jonathan's continued contributions to personalized medicine and Caris' industry-leading effort to bring precise and targeted diagnostics, prognostics and theranostics to physicians and patients."

Dr. George Poste, who is also a Vice Chairman on the Caris Life Sciences board, received the lifetime achievement award in 2009.

Dr. Knowles joined the Caris Life Sciences Board of Directors on September 1, 2009 and accepted the position of Vice Chairman starting January 1, 2010. He accepted the additional position of Chief Scientific Officer in May 2010. His career has included both academic and commercial success, as he has most recently served as President of Group Research at Roche, as well as a member of that organization's Corporate Executive Committee. He was also a member of the Genentech Board for 12 years and a member of the Chugai Board for seven.

Dr. Knowles attended Magdalen College School in Oxford and received a first class honours degree in molecular genetics from the University of East Anglia in Norwich, England. He received his PhD in genetics of mitochondria with Professor G.H. Beale FRS from the University of Edinburgh in Scotland. He has been recently appointed a professor of translational medicine at Ecole Polytechnique Federale de Lausanne in Switzerland, has been awarded a distinguished professorship in personalized health care at the Finnish Institute for Molecular Medicine at the University of Helsinki, and has been appointed as a visiting chair at the University of Oxford. In addition, he is a member of the European Molecular Biology Organization and a William Pitt Fellow of Pembroke College Cambridge.

About Caris Life Sciences

Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing the Carisome(TM) platform, a proprietary, blood-based technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, operates laboratories in the Dallas, Phoenix and Boston metro areas and is entering the European markets through its first international location, in Switzerland. For more information, visit www.carislifesciences.com.

CONTACT: Caris Life Sciences
 Media Inquiries:
 Holly Clark
 214-596-7060
 [email protected]
 
 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.